Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases

Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases
Theravance Biopharma Ireland Limited, a Theravance Biopharma subsidiary, and Janssen Biotech have joined forces to develop and commercialize the investigational therapy TD-1473 as a treatment for inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis. TD-1473 is an orally administered, highly specific inhibitor of the Janus kinase (JAK) family of enzymes, which play a critical

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *